All In Biotech

Drug Trial Radar · NCT06868849

A Study of JMT203 in Patients With Cancer Cachexia

A Phase Ia/II, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of JMT203 in Patients With Cancer Cachexia

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 307 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

307

Planned (sponsor's estimate)

Start

May 15, 2024

Primary completion

Aug 14, 2027

Study completion May 15, 2029

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
First posted
Mar 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase Ia/II, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of JMT203 in Patients with Cancer Cachexia

Conditions

  • Non Small Cell Lung Cancer
  • Pancreatic Cancer
  • Cancer Cachexia
  • Colorectal Cancer Cachexia
  • Pancreatic Cancer Cachexia

Interventions

  • JMT203 InjectionDrug

    Drug:JMT203 Injection * Anti-GFRAL monoclonal antibody * Will be injected subcutaneously once per cycle (3 weeks, on Day 1) for 12 weeks, or will be injected subcutaneously once per cycle (3 weeks, on Day 1).

  • JMT203 InjectionDrug

    Drug:JMT203 Injection * Anti-GFRAL monoclonal antibody * Will be injected subcutaneously once per cycle (3 weeks, on Day 1) for 12 weeks, or will be injected subcutaneously once per cycle (3 weeks, on Day 1).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ia: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs).Time frame: Up to 90 days after the last dose of JMT203
  2. Phase Ia: Incidence of dose-limiting toxicity (DLT) eventsTime frame: Up to 21 days after the first dose of JMT203
  3. Phase Ia: MTD (if applicable).Time frame: Up to 90 days post last dose
  4. Phase Ia: RDE.Time frame: Up to 90 days post last dose
  5. Phase Ib: Average change in body weight from baseline at each assessment timepoint within 12 weeks.Time frame: Within 12 weeks from baseline
  6. Phase II: RP3DTime frame: Approximately 1 year from baseline

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sir run run shaw Hospital

    Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.